Switch theme
Sign up to access all valuation multiples
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
2018
452
LTM Revenue $67.4M
LTM EBITDA -$243M
$229M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Phathom Pharmaceuticals has a last 12-month revenue of $67.4M and a last 12-month EBITDA of -$243M.
In the most recent fiscal year, Phathom Pharmaceuticals achieved revenue of $0.7M and an EBITDA of -$159M.
Phathom Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Phathom Pharmaceuticals valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | $0.7M | $50.5M | $67.4M | XXX |
| Gross Profit | n/a | n/a | $0.5M | XXX | XXX |
| Gross Margin | NaN% | NaN% | 1% | XXX | XXX |
| EBITDA | -$170M | -$159M | -$249M | -$243M | XXX |
| EBITDA Margin | -Infinity% | -23321% | -494% | -360% | XXX |
| Net Profit | -$144M | -$198M | -$202M | XXX | XXX |
| Net Margin | -Infinity% | -28992% | -399% | XXX | XXX |
| Net Debt | n/a | n/a | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Phathom Pharmaceuticals's stock price is $6.
Phathom Pharmaceuticals has current market cap of $388M, and EV of $229M.
See Phathom Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $229M | $388M | XXX | XXX | XXX | XXX | $-5.14 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Phathom Pharmaceuticals has market cap of $388M and EV of $229M.
Phathom Pharmaceuticals's trades at 3.4x LTM EV/Revenue multiple, and -0.9x LTM EBITDA.
Analysts estimate Phathom Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Phathom Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $229M | XXX | XXX | XXX |
| EV/Revenue | 4.5x | XXX | XXX | XXX |
| EV/EBITDA | -0.9x | XXX | XXX | XXX |
| P/E | -1.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPhathom Pharmaceuticals's NTM/LTM revenue growth is 191%
Phathom Pharmaceuticals's revenue per employee for the last fiscal year averaged $2K, while opex per employee averaged $0.4M for the same period.
Over next 12 months, Phathom Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Phathom Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Phathom Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 7304% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -494% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 57% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -303% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $2K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 7317% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 24608% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Phathom Pharmaceuticals acquired XXX companies to date.
Last acquisition by Phathom Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Phathom Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Phathom Pharmaceuticals founded? | Phathom Pharmaceuticals was founded in 2018. |
| Where is Phathom Pharmaceuticals headquartered? | Phathom Pharmaceuticals is headquartered in United States of America. |
| How many employees does Phathom Pharmaceuticals have? | As of today, Phathom Pharmaceuticals has 452 employees. |
| Who is the CEO of Phathom Pharmaceuticals? | Phathom Pharmaceuticals's CEO is Ms. Terrie Curran. |
| Is Phathom Pharmaceuticals publicy listed? | Yes, Phathom Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Phathom Pharmaceuticals? | Phathom Pharmaceuticals trades under PHAT ticker. |
| When did Phathom Pharmaceuticals go public? | Phathom Pharmaceuticals went public in 2019. |
| Who are competitors of Phathom Pharmaceuticals? | Similar companies to Phathom Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Phathom Pharmaceuticals? | Phathom Pharmaceuticals's current market cap is $388M |
| What is the current revenue of Phathom Pharmaceuticals? | Phathom Pharmaceuticals's last 12-month revenue is $67.4M. |
| What is the current EBITDA of Phathom Pharmaceuticals? | Phathom Pharmaceuticals's last 12-month EBITDA is -$243M. |
| What is the current EV/Revenue multiple of Phathom Pharmaceuticals? | Current revenue multiple of Phathom Pharmaceuticals is 3.4x. |
| What is the current EV/EBITDA multiple of Phathom Pharmaceuticals? | Current EBITDA multiple of Phathom Pharmaceuticals is -0.9x. |
| What is the current revenue growth of Phathom Pharmaceuticals? | Phathom Pharmaceuticals revenue growth between 2023 and 2024 was 7304%. |
| Is Phathom Pharmaceuticals profitable? | Yes, Phathom Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
